LONDON - Microscience Ltd. pulled its £40 million (US$74.5 million) initial public offering on London's Alternative Investment Market after refusing to compromise on a £120 million to £140 million valuation. (BioWorld International)
LONDON - Microscience Ltd. pulled its £40 million (US$74.5 million) initial public offering on London's Alternative Investment Market after refusing to compromise on a £120 million to £140 million valuation. (BioWorld International)
LONDON - Cyclacel Group plc announced a dual listing on Nasdaq and the London Stock Exchange seeking £26.6 million (US$48 million) to charge development of the lead compound from its orally available cyclin dependent kinase inhibitor program in a bid to be first to market. (BioWorld International)
LONDON - Cyclacel Group plc announced a dual listing on Nasdaq and the London Stock Exchange seeking £26.6 million (US$48 million) to charge development of the lead compound from its orally available cyclin dependent kinase inhibitor program in a bid to be first to market. (BioWorld International)
LONDON - Cyclacel Group plc announced a dual listing on Nasdaq and the London Stock Exchange seeking £26.6 million (US$48 million) to charge development of the lead compound from its orally available cyclin dependent kinase inhibitor program in a bid to be first to market. (BioWorld Today)
LONDON - Cyclacel Group plc announced a dual listing on Nasdaq and the London Stock Exchange seeking £26.6 million (US$48 million) to charge development of the lead compound from its orally available cyclin dependent kinase inhibitor program in a bid to be first to market. (BioWorld Today)
